p53 anticorps (Tumor Protein P53) (AA 14-289)

Details for Product anti-TP53 Antibody No. ABIN967419, Fournisseur: Connectez-vous pour afficher
Antigène
  • BCC7
  • LFS1
  • P53
  • TRP53
  • p53
  • Trp53
  • brp53
  • drp53
  • etID22686.5
  • fb40d06
  • wu:fb40d06
  • zgc:111919
  • Tp53
  • bbl
  • bfy
  • bhy
  • p44
  • tp53
  • Xp53
  • TP53
  • tumor protein p53
  • cellular tumor antigen p53
  • transformation related protein 53
  • tumor protein p53 L homeolog
  • TP53
  • CpipJ_CPIJ002758
  • Tp53
  • tp53
  • Trp53
  • tp53.L
Épitope
AA 14-289
168
124
77
76
73
72
66
60
59
58
47
45
41
38
35
34
33
24
24
23
23
22
21
21
17
15
15
15
15
15
15
15
14
13
13
12
11
10
9
9
9
8
8
8
7
7
7
7
7
7
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivité
Poulet, Boeuf (Vache), Hamster, Humain, Singe, Souris, Rat (Rattus)
2521
585
483
292
154
103
103
61
54
26
23
22
17
16
16
14
7
6
5
4
4
4
4
3
3
3
2
1
1
Hôte
Souris
1522
1121
7
5
1
1
1
1
Clonalité (Clone)
Monoclonal ()
Conjugué
Cet anticorp p53 est non-conjugé
79
79
67
52
45
36
34
32
23
23
21
20
19
19
19
19
18
18
18
18
15
14
14
12
12
12
12
12
11
8
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
5
2
2
2
Application
Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Western Blotting (WB)
2095
962
865
776
663
646
418
293
257
155
110
90
75
41
32
19
16
15
13
6
4
4
4
3
2
2
1
1
1
1
1
1
1
1
1
1
Options
Fournisseur
Connectez-vous pour afficher
N° du produit (Fournisseur)
Connectez-vous pour afficher
Marque BD Pharmingen™
Immunogène Human p53 aa. 14-289
Clone PAb 240
Isotype IgG1
 Réactivité croisée Souris, Rat (Rattus), Hamster, Singe, Boeuf (Vache), Poulet
Attributs du produit 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Plasmids, Primers & others Plasmids, Primers & others p53 products on genomics-online (e.g. as negative or positive controls)
Antigène
Autre désignation p53 (TP53 Antibody Extrait)
Sujet P53 is a nuclear phosphoprotein which acts as a tumor suppressor by providing a cell cycle checkpoint for DNA damage during S-phase. Mutations in wildtype p53 can indirectly alter the DNA binding and transcription factor activity of p53. By altering expression of genes normally regulated by p53, these mutations can result in both a loss of tumor suppressor function and a gain of oncogenic function. The majority of mutations in the p53 gene are missense mutations which alter the identity of an amino acid. These mutations may alter the conformation and thus increase the stability of the mutant p53 protein. p53 is expressed in all vertebrate species examined. p53 may be overexpressed in transformed cell lines, where it forms complexes with viral oncogenes including SV40 large T antigen and the adenovirus protein, E1B. p53 migrates at ~53 kDa on SDS-PAGE.
PAb 240 reacts with a conformational epitope between amino acids 156 and 214 of native p53. As such, Pab 240 recognizes only certain mutant forms of p53, as determined by immunoprecipitation. It detects both mutant and wildtype p53 in western blot analysis and immunohistochemistry of frozen tissue sections. It is thought that p53 mutations exert a common conformational change which results in expression of the Pab 240-specific epitope on mutant p53 molecules. A recombinant fusion protein of p53 sequence including amino acids 14-289 was used as immunogen.
Poids moléculaire 53 kDa
Pathways Signalisation p53, Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy
Indications d'application SV40-transformed COS-7 monkey kidney cells (ATCC CRL-1651) or other SV40-transformed cell lines are suggested as positive controls.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Agent conservateur Sodium azide
Précaution d'utilisation This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock 4 °C
Stockage commentaire Store undiluted at 4°C.
Images (Fournisseur)
Western Blotting (WB) image for anti-Tumor Protein P53 (TP53) (AA 14-289) antibody (ABIN967419) Western blot analysis of p53. Lysate from SV40-transformed COS-7 cells were probed wi...
 image for anti-Tumor Protein P53 (TP53) (AA 14-289) antibody (ABIN967419) anti-Tumor Protein P53 (TP53) (AA 14-289) antibody (Image 2)
Western Blotting (WB) image for anti-Tumor Protein P53 (TP53) (AA 14-289) antibody (ABIN967419) anti-Tumor Protein P53 (TP53) (AA 14-289) antibody (Image 3)
Produit citée dans: Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." dans: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, 1994 (PubMed).

Said, Barrera, Shintaku, Nakamura, Koeffler: "Immunohistochemical analysis of p53 expression in malignant lymphomas." dans: The American journal of pathology, Vol. 141, Issue 6, pp. 1343-8, 1993 (PubMed).

Moore, Teresky, Levine, Seiberg: "p53 mutations are not selected for in simian virus 40 T-antigen-induced tumors from transgenic mice." dans: Journal of virology, Vol. 66, Issue 2, pp. 641-9, 1992 (PubMed).

Walker, Dearing, Lane, Varley: "Expression of p53 protein in infiltrating and in-situ breast carcinomas." dans: The Journal of pathology, Vol. 165, Issue 3, pp. 203-11, 1992 (PubMed).

Bártek, Bártková, Vojt?sek, Stasková, Lukás, Rejthar, Kovarík, Midgley, Gannon, Lane: "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." dans: Oncogene, Vol. 6, Issue 9, pp. 1699-703, 1991 (PubMed).

Background publications Vojt?sek, Bártek, Midgley, Lane: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." dans: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, 1992 (PubMed).

Gannon, Greaves, Iggo, Lane: "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form." dans: The EMBO journal, Vol. 9, Issue 5, pp. 1595-602, 1990 (PubMed).

Avez-vous cherché autre chose?